Press Enter to search · Esc to close
Two new trials in The Lancet put the first credible oral, non-peptide GLP-1 drugs on the runway — a shift that could change who actually gets access to this class.
A once-daily oral GLP-1, fresh data linking the class to lower lumbar disease risk, and a network meta-analysis hinting at a nuanced colorectal cancer question. Here's what the moderate evidence actually says.
A new phase 3 trial shows a once-daily pill can deliver meaningful weight loss without a needle — and that small detail could change who actually gets treated.
The first non-peptide oral GLP-1 has real bioavailability data, prescriptions to women of reproductive age are climbing fast, and social-media ads are quietly rewriting how the public reads the science.
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.